(Oslo, Norway, 26 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ('Bionor' or the 'Company', ticker 'BIONOR') regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES

Primary insider notification - Maja A. Sommerfelt

Maja A. Sommerfelt, a primary insider of the Company, has today exercised 499,377 Subscription Rights and following such transaction holds the following interests in the Company:

Name Position Shares Subscription Rights
in the Rights Issue

Maja A. Sommerfelt

VP, Director Research &
External Innovation
818,664 0

The subscription price for the shares is NOK 0.10 per share.

Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com
Jens Krøis, CFO, +45 208 01 668, jk@bionorpharma.com

Link to announcement in pdf

Bionor Pharma ASA published this content on 26 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 September 2016 08:20:02 UTC.

Original documenthttp://www.bionorpharma.com/en/Media/News/2016/Financial/Mandatory+Notification+of+Trade+-+Sommerfelt.b7C_wlDS3E.ips

Public permalinkhttp://www.publicnow.com/view/D9DB1A38B3DBA346020CC42B6B37E1DEA255E308